Advances in Coronary Microvascular Dysfunction and Metabolic Syndrome

doi:10.12114/j.issn.1007-9572.2023.0250

Abstract

Abstract:

Coronary microvascular dysfunction (CMD) and metabolic syndrome (MetS) have attracted much attention recently due to the adverse effects on cardiovascular system. CMD is a potential factor leading to myocardial ischemia, which is closely related to the occurrence, progression and poor prognosis of cardiovascular diseases. MetS is a group of metabolic diseases caused by a combination of genetic and environmental factors. There is an association between CMD and MetS, understanding the complex interactions between the two diseases is essential for developing effective prevention and treatment strategies. This article aims to review the development of MetS and CMD, and the relationship of the components of MetS with CMD, as well as the diagnosis, treatment and future research directions of these diseases.

Key words: Coronary heart diseases, Coronary microvascular dysfunction, Metabolic syndrome, Review, Editorial

摘要：

近年来，冠状动脉微循环障碍（CMD）和代谢综合征（MetS）因对心血管造成不利影响而备受关注。CMD是导致心肌缺血的一种潜在因素，与心血管疾病的发生、进展和不良预后密切相关。MetS是一组由遗传和环境因素共同作用而引起的代谢性疾病。CMD和MetS之间存在一定的关联，了解两种疾病之间复杂的相互作用对于制订有效的预防和治疗策略至关重要。本文旨在综述二者的发展历程、MetS各组分与CMD之间的关系、疾病诊疗以及未来研究方向，以期为临床提供借鉴。

关键词: 冠状动脉心脏病, 冠状动脉微循环障碍, 代谢综合征, 综述, 述评

ZHU Chunlin,GAO Jie. Advances in Coronary Microvascular Dysfunction and Metabolic Syndrome[J]. Chinese General Practice, 2024, 27(03): 273-279. DOI: 10.12114/j.issn.1007-9572.2023.0250.
朱春临,高洁. 冠状动脉微循环障碍与代谢综合征的研究进展[J]. 中国全科医学, 2024, 27(03): 273-279. DOI: 10.12114/j.issn.1007-9572.2023.0250.

References 74

[1]	VANCHERI F，LONGO G，VANCHERI S，et al. Coronary microvascular dysfunction[J]. J Clin Med，2020，9（9）：2880. DOI：10.3390/jcm9092880.
[2]	CHEN C，WEI J，ALBADRI A，et al. Coronary microvascular dysfunction - epidemiology，pathogenesis，prognosis，diagnosis，risk factors and therapy[J]. Circ J，2016，81（1）：3-11. DOI：10.1253/circj.CJ-16-1002.
[3]	ECKEL R H，GRUNDY S M，ZIMMET P Z. The metabolic syndrome[J]. Lancet，2005，365（9468）：1415-1428. DOI：10.1016/S0140-6736(05)66378-7.
[4]	LU J L，WANG L M，LI M，et al. Metabolic syndrome among adults in China：the 2010 China noncommunicable disease surveillance[J]. J Clin Endocrinol Metab，2017，102（2）：507-515. DOI：10.1210/jc.2016-2477.
[5]	LIKOFF W，SEGAL B L，KASPARIAN H. Paradox of normal selective coronary arteriograms in patients considered to have unmistakable coronary heart disease[J]. N Engl J Med，1967，276（19）：1063-1066. DOI：10.1056/NEJM196705112761904.
[6]	KEMP H G Jr，VOKONAS P S，COHN P F，et al. The anginal syndrome associated with normal coronary arteriograms. Report of a six year experience[J]. Am J Med，1973，54（6）：735-742. DOI：10.1016/0002-9343(73)90060-0.
[7]	Management of Stable Angina Pectoris. Recommendations of the task force of the European society of cardiology[J]. Eur Heart J，1997，18（3）：394-413. DOI：10.1093/oxfordjournals.eurheartj.a015259.
[8]	VERHOEFF B J，SIEBES M，MEUWISSEN M，et al. Influence of percutaneous coronary intervention on coronary microvascular resistance index[J]. Circulation，2005，111（1）：76-82. DOI：10.1161/01.CIR.0000151610.98409.2F.
[9]	CAMICI P G，CREA F. Medical progress-coronary microvascular dysfunction[J]. New England Journal of Medicine，2007，356（8）：830-840. DOI：10.1056/NEJMra061889.
[10]	Task Force Members，MONTALESCOT G，SECHTEM U，et al. 2013 ESC guidelines on the management of stable coronary artery disease：the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J，2013，34（38）：2949-3003. DOI：10.1093/eurheartj/eht296.
[11]	REAVEN G. Banting Lecture 1988. Role of insulin resistance in human disease. 1988[J]. Nutrition，1997，13（1）：65-66. DOI：10.1016/s0899-9007(96)00380-2.
[12]	ZIMMET P Z，MCCARTY D J，DE COURTEN M P. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome[J]. J Diabetes Complications，1997，11（2）：60-68. DOI：10.1016/s1056-8727(96)00090-6.
[13]	WHO. Definition，diagnosis and classification of diabetes mellitus and its complications[J]. Diabetic Medicine，1999. DOI：10.1002/(SICI)1096-9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S.
[14]	Expert Panel on Detection E. Executive summary of the third report of the national cholesterol education program（NCEP）expert panel on detection，evaluation，and treatment of high blood cholesterol in adults（adult treatment panel Ⅲ）[J]. JAMA，2001，285（19）：2486-2497. DOI：10.1001/jama.285.19.2486.
[15]	GRUNDY S M，HANSEN B，SMITH S C Jr，et al. Clinical management of metabolic syndrome：report of the American Heart Association/National Heart，Lung，and Blood Institute/American Diabetes Association conference on scientific issues related to management[J]. Arterioscler Thromb Vasc Biol，2004，24（2）：e19-24. DOI：10.1161/01.ATV.0000112379.88385.67.
[16]	ALBERTI K G，ZIMMET P，SHAW J，et al. The metabolic syndrome—a new worldwide definition[J]. Lancet，2005，366（9491）：1059-1062. DOI：10.1016/S0140-6736(05)67402-8.
[17]	ALBERTI K G M M，ECKEL R H，GRUNDY S M，et al. Harmonizing the metabolic syndrome：a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart，Lung，and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation，2009，120（16）：1640-1645. DOI：10.1161/CIRCULATIONAHA.109.192644.
[18]	SANDERS K. Coronary-artery disease and obesity[J]. Lancet，1959，274（7100）：432-435. DOI：10.1016/S0140-6736(59)90419-2.
[19]	DEFRONZO R A，FERRANNINI E. Insulin resistance. A multifaceted syndrome responsible for NIDDM，obesity，hypertension，dyslipidemia，and atherosclerotic cardiovascular disease[J]. Diabetes Care，1991，14（3）：173-194. DOI：10.2337/diacare.14.3.173.
[20]	NOON J P，WALKER B R，WEBB D J，et al. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure[J]. J Clin Invest，1997，99（8）：1873-1879. DOI：10.1172/JCI119354.
[21]	JONK A M，HOUBEN A J，DE JONGH R T，et al. Microvascular dysfunction in obesity：a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension[J]. Physiology，2007，22：252-260. DOI：10.1152/physiol.00012.2007.
[22]	WALLIS M G，WHEATLEY C M，RATTIGAN S，et al. Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats[J]. Diabetes，2002，51（12）：3492-3498. DOI：10.2337/diabetes.51.12.3492.
[23]	SERNÉ E H，GANS R O，TER MAATEN J C，et al. Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions[J]. Cardiovasc Res，2001，49（1）：161-168. DOI：10.1016/s0008-6363(00)00198-x.
[24]	WANG R N，LI X，HUANGFU S H，et al. Combining body mass index with waist circumference to assess coronary microvascular function in patients with non-obstructive coronary artery disease[J]. J Nucl Cardiol，2022，29（5）：2434-2445. DOI：10.1007/s12350-021-02788-3.
[25]	BAGI Z，BROSKOVA Z，FEHER A. Obesity and coronary microvascular disease - implications for adipose tissue-mediated remote inflammatory response[J]. Curr Vasc Pharmacol，2014，12（3）：453-461. DOI：10.2174/1570161112666140423221843.
[26]	GLATZ J F C，LUIKEN J J F P. From fat to FAT（CD36/SR-B2）：understanding the regulation of cellular fatty acid uptake[J]. Biochimie，2017，136：21-26. DOI：10.1016/j.biochi.2016.12.007.
[27]	OBRADOVIC M，SUDAR-MILOVANOVIC E，SOSKIC S，et al. Leptin and obesity：role and clinical implication[J]. Front Endocrinol，2021，12：585887. DOI：10.3389/fendo.2021.585887.
[28]	ACHARI A E，JAIN S K. Adiponectin，a therapeutic target for obesity，diabetes，and endothelial dysfunction[J]. Int J Mol Sci，2017，18（6）：1321. DOI：10.3390/ijms18061321.
[29]	KARACA Ü，SCHRAM M T，HOUBEN A J，et al. Microvascular dysfunction as a link between obesity，insulin resistance and hypertension[J]. Diabetes Res Clin Pract，2014，103（3）：382-387. DOI：10.1016/j.diabres.2013.12.012.
[30]	OWEN M K，NOBLET J N，SASSOON D J，et al. Perivascular adipose tissue and coronary vascular disease[J]. Arterioscler Thromb Vasc Biol，2014，34（8）：1643-1649. DOI：10.1161/ATVBAHA.114.303033.
[31]	COSTA R M，NEVES K B，TOSTES R C，et al. Perivascular adipose tissue as a relevant fat depot for cardiovascular risk in obesity[J]. Front Physiol，2018，9：253. DOI：10.3389/fphys.2018.00253.
[32]	VILLACORTA L，CHANG L. The role of perivascular adipose tissue in vasoconstriction，arterial stiffness，and aneurysm[J]. Horm Mol Biol Clin Investig，2015，21（2）：137-147. DOI：10.1515/hmbci-2014-0048.
[33]	TAQUETI V R，DI CARLI M F. Coronary microvascular disease pathogenic mechanisms and therapeutic options：JACC state-of-the-art review[J]. J Am Coll Cardiol，2018，72（21）：2625-2641. DOI：10.1016/j.jacc.2018.09.042.
[34]	BLOOMGARDEN Z T. Insulin resistance，dyslipidemia，and cardiovascular disease[J]. Diabetes Care，2007，30（8）：2164-2170. DOI：10.2337/dc07-zb08.
[35]	SUN D N，WANG J，TOAN S，et al. Molecular mechanisms of coronary microvascular endothelial dysfunction in diabetes mellitus：focus on mitochondrial quality surveillance[J]. Angiogenesis，2022，25（3）：307-329. DOI：10.1007/s10456-022-09835-8.
[36]	HAYDEN M R. Overview and new insights into the metabolic syndrome：risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease[J]. Medicina，2023，59（3）：561. DOI：10.3390/medicina59030561.
[37]	JIA G H，HILL M A，SOWERS J R. Diabetic cardiomyopathy：an update of mechanisms contributing to this clinical entity[J]. Circ Res，2018，122（4）：624-638. DOI：10.1161/CIRCRESAHA.117.311586.
[38]	SHIVU G N，PHAN T T，ABOZGUIA K，et al. Relationship between coronary microvascular dysfunction and cardiac energetics impairment in type 1 diabetes mellitus[J]. Circulation，2010，121（10）：1209-1215. DOI：10.1161/CIRCULATIONAHA.109.873273.
[39]	BUELT A，RICHARDS A，JONES A L. Hypertension：new guidelines from the international society of hypertension[J]. Am Fam Physician，2021，103（12）：763-765.
[40]	MILLS K T，STEFANESCU A，HE J. The global epidemiology of hypertension[J]. Nat Rev Nephrol，2020，16（4）：223-237. DOI：10.1038/s41581-019-0244-2.
[41]	BRUNO R M，MASI S，TADDEI M，et al. Essential hypertension and functional microvascular ageing[J]. High Blood Press Cardiovasc Prev，2018，25（1）：35-40. DOI：10.1007/s40292-017-0245-9.
[42]	VALENSI P. Autonomic nervous system activity changes in patients with hypertension and overweight：role and therapeutic implications[J]. Cardiovasc Diabetol，2021，20（1）：170. DOI：10.1186/s12933-021-01356-w.
[43]	PADRO T，MANFRINI O，BUGIARDINI R，et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'[J]. Cardiovasc Res，2020，116（4）：741-755. DOI：10.1093/cvr/cvaa003.
[44]	ALONSO R，MATA P，ANDRES R D，et al. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin[J]. Atherosclerosis，2001，157（2）：423-429. DOI：10.1016/s0021-9150(00)00733-4.
[45]	REINDL M，REINSTADLER S J，FEISTRITZER H J，et al. Relation of low-density lipoprotein cholesterol with microvascular injury and clinical outcome in revascularized ST-elevation myocardial infarction[J]. J Am Heart Assoc，2017，6（10）：e006957. DOI：10.1161/JAHA.117.006957.
[46]	STOKES K Y，CALAHAN L，RUSSELL J M，et al. Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction[J]. Microcirculation，2006，13（5）：377-388. DOI：10.1080/10739680600745877.
[47]	SCALIA R，APPEL J Z，LEFER A M. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit：role of P-selectin，ICAM-1，and VCAM-1[J]. Arterioscler Thromb Vasc Biol，1998，18（7）：1093-1100. DOI：10.1161/01.atv.18.7.1093.
[48]	STOKES K Y，CALAHAN L，HAMRIC C M，et al. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation[J]. Am J Physiol Heart Circ Physiol，2009，296（3）：H689-697. DOI：10.1152/ajpheart.00962.2008.
[49]	STOKES K Y，COOPER D，TAILOR A，et al. Hypercholesterolemia promotes inflammation and microvascular dysfunction：role of nitric oxide and superoxide[J]. Free Radic Biol Med，2002，33（8）：1026-1036. DOI：10.1016/s0891-5849(02)01015-8.
[50]	BERLINER J A，LEITINGER N，TSIMIKAS S. The role of oxidized phospholipids in atherosclerosis[J]. J Lipid Res，2009，50（Suppl）：S207-212. DOI：10.1194/jlr.R800074-JLR200.
[51]	PIRILLO A，NORATA G D，CATAPANO A L. LOX-1，OxLDL，and atherosclerosis[J]. Mediators Inflamm，2013，2013：152786. DOI：10.1155/2013/152786.
[52]	SAKURAI K，SAWAMURA T. Stress and vascular responses：endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1：close relationships with oxidative stress[J]. J Pharmacol Sci，2003，91（3）：182-186. DOI：10.1254/jphs.91.182.
[53]	TSIMIKAS S，BRILAKIS E S，MILLER E R，et al. Oxidized phospholipids，Lp（a）lipoprotein，and coronary artery disease[J]. N Engl J Med，2005，353（1）：46-57. DOI：10.1056/NEJMoa043175.
[54]	INSTITORIS A，GORDON G R. A tense relationship between capillaries and pericytes[J]. Nat Neurosci，2021，24（5）：615-617. DOI：10.1038/s41593-021-00853-1.
[55]	倪青.代谢综合征病证结合诊疗指南[J/OL]. [2023-06-19].
[56]	PÉREZ-MARTÍNEZ P，MIKHAILIDIS D P，ATHYROS V G，et al. Lifestyle recommendations for the prevention and management of metabolic syndrome：an international panel recommendation[J]. Nutr Rev，2017，75（5）：307-326. DOI：10.1093/nutrit/nux014.
[57]	WIDMER R J，FLAMMER A J，LERMAN L O，et al. The Mediterranean diet，its components，and cardiovascular disease[J]. Am J Med，2015，128（3）：229-238. DOI：10.1016/j.amjmed.2014.10.014.
[58]	BACH-FAIG A，BERRY E M，LAIRON D，et al. Mediterranean diet pyramid today. Science and cultural updates[J]. Public Health Nutr，2011，14（12A）：2274-2284. DOI：10.1017/S1368980011002515.
[59]	MARTÍNEZ-GONZÁLEZ M A，GEA A，RUIZ-CANELA M. The Mediterranean diet and cardiovascular health[J]. Circ Res，2019，124（5）：779-798. DOI：10.1161/CIRCRESAHA.118.313348.
[60]	KASTORINI C M，MILIONIS H J，ESPOSITO K，et al. The effect of Mediterranean diet on metabolic syndrome and its components：a meta-analysis of 50 studies and 534，906 individuals[J]. J Am Coll Cardiol，2011，57（11）：1299-1313. DOI：10.1016/j.jacc.2010.09.073.
[61]	PAPADAKI A，NOLEN-DOERR E，MANTZOROS C S. The effect of the Mediterranean diet on metabolic health：a systematic review and meta-analysis of controlled trials in adults[J]. Nutrients，2020，12（11）：3342. DOI：10.3390/nu12113342.
[62]	许瀚，尹毅，赵燕. 运动干预对成人代谢综合征患者心血管危险因素影响的Meta分析[J]. 中国体育科技，2020，56（5）：59-70. DOI：10.16470/j.csst.2020065.
[63]	MAO S，ZHANG X X，CHEN M G，et al. Beneficial effects of Baduanjin exercise on left ventricular remodelling in patients after acute myocardial infarction：an exploratory clinical trial and proteomic analysis[J]. Cardiovasc Drugs Ther，2021，35（1）：21-32. DOI：10.1007/s10557-020-07047-0.
[64]	廖色青，梁云花，夏令琼，等. 中医传统健身法八段锦对代谢综合征患者的影响[J]. 现代中西医结合杂志，2013，22（23）：2560-2561. DOI：10.3969/j.issn.1008-8849.2013.23.022.
[65]	金娟，李洋，岑璐，等. 健身气功八段锦对代谢综合征影响的研究[J]. 广州中医药大学学报，2021，38（7）：1426-1431. DOI：10.13359/j.cnki.gzxbtcm.2021.07.023.
[66]	彭永，朱欢，刘尧峰，等. 24周太极拳结合弹力带抗阻运动对2型糖尿病患者足背微循环功能的影响[J]. 首都体育学院学报，2023，35（1）：77-85. DOI：10.14036/j.cnki.cn11-4513.2023.01.009.
[67]	BROOKS S，BRANYAN K W，DEVALLANCE E，et al. Psychological stress-induced cerebrovascular dysfunction：the role of metabolic syndrome and exercise[J]. Exp Physiol，2018，103（5）：761-776. DOI：10.1113/EP086892.
[68]	杨婷婷，ANNE F，孔维敏. 睡眠不足与心血管代谢性疾病相关性研究进展[J]. 重庆医学，2017，46（24）：3430-3433. DOI：10.3969/j.issn.1671-8348.2017.24.039.
[69]	HAZLETT-STEVENS H，SINGER J，CHONG A. Mindfulness-based stress reduction and mindfulness-based cognitive therapy with older adults：a qualitative review of randomized controlled outcome research[J]. Clin Gerontol，2019，42（4）：347-358. DOI：10.1080/07317115.2018.1518282.
[70]	薛婷，崔东红. 冥想降低心血管疾病风险的作用[J]. 中华行为医学与脑科学杂志，2019，28（11）：1043-1047. DOI：10.3760/cma.j.issn.1674-6554.2019.11.016.
[71]	陈浩，龚涛，王晓霞，等. 中国多学科微血管疾病诊断与治疗专家共识[J]. 中国循环杂志，2020，35（12）：1149-1165. DOI：10.3969/j.issn.1000-3614.2020.12.001.
[72]	KNUUTI J，WIJNS W，SARASTE A，et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J，2020，41（3）：407-477. DOI：10.1093/eurheartj/ehz425.
[73]	AMINIAN A，ZAJICHEK A，ARTERBURN D E，et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity[J]. JAMA，2019，322（13）：1271-1282. DOI：10.1001/jama.2019.14231.
[74]	WU M D，MOCCETTI F，BROWN E，et al. Lipoprotein apheresis acutely reverses coronary microvascular dysfunction in patients with severe hypercholesterolemia[J]. JACC Cardiovasc Imaging，2019，12（8 Pt 1）：1430-1440. DOI：10.1016/j.jcmg.2018.05.001.